Sorafenib in Newly Diagnosed High Grade Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
GlioblastomaGliosarcomaAnaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma
Interventions
DRUG

Sorafenib dose escalation

Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid

Trial Locations (1)

1211

Geneva University Hospital (Hopitaux Universitaires de Geneve), Department of Oncology, Geneva

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University Hospital, Geneva

OTHER

NCT00884416 - Sorafenib in Newly Diagnosed High Grade Glioma | Biotech Hunter | Biotech Hunter